 After treatment discontinuation, subjects will have a pre-hematopoietic stem cell transplant HSCTend-of-treatment visit within 7 days after treatment discontinuation, followed by a 30-day follow-up for safety, in which a telephone contact with the subject is sufficient unless any assessment must be repeated for resolution of treatment-related adverse events AEs. After that, long term follow-up will be done every 3 months up to 3 years from the subjects end-of-treatment visit. 